

Indoleamine 2,3-dioxygenase (IDO) is expressed at feto-placental unit throughout mouse gestation: An immunohistochemical study

Hemmati, Shayda (M.Sc.)¹; Jeddi-Tehrani, Mahmood (Ph.D.)²; Torkabadi, Ebrahim (M.Sc.)³; Ghassemi, Jamileh (B.Sc.)³; Kazemi sefat, Golnaz Ensieh (B.Sc.)³; Danesh, Parivash (B.Sc.)⁴; Barzegar Yarmohammadi, Leila (M.Sc.)²; Akhondi, Mohammad Mehdi (Ph.D.)³; Zarnani, Amir Hassan (D.M.T., Ph.D.)^{4,5*}

1- Department of Cell and Molecular Biology, Khatam University, Tehran, Iran.

2- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.

3- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.

4- Immunology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

5- Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.

Abstract

Introduction: The cells expressing Indoleamine 2, 3-dioxygenase (IDO) in feto-maternal interface mediate tryptophan catabolism, hence protect allogeneic fetus from lethal rejection by maternal immune responses. In this study, we report immunolocalization of IDO⁺ cells in murine reproductive tract and placenta throughout mouse pregnancy by immunohistochemistry.

Materials and Methods: Syngeneic pregnant mice were examined for vaginal plug to discover about their state of pregnancy. A total of three pregnant mice were examined at each stage. The examination was further confirmed by the detection of sperm in vaginal smear. On the gestational days of 2nd, 12th and 18th, the uterus and oviduct were removed and expression of IDO was investigated in the endometrium, placenta and oviduct by immunohistochemistry.

Results: Our results showed that IDO is expressed consistently in feto-maternal interface throughout pregnancy. In endometrium, expression of IDO was predominantly confined to luminal and glandular epithelial cells. Cells at junctional and labyrinth zones of placenta showed strong IDO immunoreactivity as well.

Conclusion: Expression of IDO at the protein level in reproductive tract of pregnant mice during entire periods of gestation points to its potential protective role in maintenance of pregnancy. In our knowledge this is the first report of expression of IDO in feto-maternal phase during murine pregnancy.

Keywords: Decidua, Endometrium, Immunohistochemistry, Indoleamine 2,3-dioxygenase, Oviduct, Placenta, Pregnancy, Tolerance.

To cite this article: Hemmati Sh, Jeddi-Tehrani M, Torkabadi E, Ghasemi J, Kazemi Sefat GE, Danesh P, et al. Indoleamine 2,3-dioxygenase (IDO) is expressed at feto-placental unit throughout mouse gestation; An immunohistochemical study. *J Reprod Infertil.* 2009;10(3): 177-83.

* Corresponding Author:
Dr. Amir Hassan Zarnani,
Nanobiotechnology
Research Center,
Avicenna Research
Institute, ACECR,
Chamran Highway,
Velenjak, Shahid Beheshti
University, Tehran, Iran.
E-mail:
zarnani25@yahoo.com
zarnani@avicenna.ac.ir

Received: Mar. 2, 2009

Accepted: Jul. 8, 2009

Introduction

A monomeric haemoprotein, Indoleamine 2, 3-dioxygenase (IDO) has a molecular mass of about 45 kDa. This enzyme catalyses the degradation of an essential amino acid, L-tryptophan, to N-formyl-kynurenine along the kynurenine pathway in mammals (1-4). Gamma-interferon has an antiproliferative effect on many tumor cells (5-7) and inhibits intracellular

pathogens such as Toxoplasma and Chlamydia (8-10), at least partly through induction of IDO and corollary tryptophan deprivation.

Some organs such as the thymus, epididymis, placenta, anterior chamber of eye, intestine and lung are among the normal tissues which express high levels of this enzyme (11-16). In these sites IDO catalyzes the metabolism of tryptophan, an

amino acid essential for T-cell proliferation and differentiation and hence controls functions of those organs (4).

T lymphocytes have been reported to lose the ability to initiate cell division under the influence of IDO (17). There is evidence that antigen presenting cells such as macrophages or dendritic cells (DCs) can inhibit T cell proliferation through IDO production, as IDO inhibition by 1-methyl tryptophan prevents suppressive effects of antigen presenting cells on T cells (18,19). In addition, the cellular expression of IDO at the maternal-fetal junction has recently attracted many attentions as a powerful mechanism for tolerance induction (20, 21). In fact, in an elegantly designed series of experiments, Munn & Mellor convincingly showed that IDO is important for the induction of tolerance toward semi-allogeneic fetus and blocking IDO resulted in rejection of all fetuses (20). Many attempts have been made to characterize the nature of IDO+ cells at the maternal-fetal interface. These studies have shown that IDO+ cells lack mouse macrophage marker F4/80 and that exist in NK- knock out mice (22). It has been demonstrated in humans that IDO expression in syncytiotrophoblasts is mainly cytoplasmic and does not occur at their maternal-facing border membrane (21). IDO expression has not been detected in the first-trimester human placenta, its expression, however, starts around the 14th week of gestation and continues until full term pregnancy. In term placenta, IDO is irregularly localized to the mesenchymal core and isolated areas of syncytiotrophoblasts (23). Kudo *et al.* showed that in-vitro stimulation of chorionic villous explants of both early and term placenta enhances the tryptophan degradation; an indirect indicator of IDO expression (24). Although, most studies have focused on IDO expression in pregnancy, some investigators have found IDO transcripts in endometrial glandular and epithelial cells and have demonstrated that IDO expression increases during menstrual cycle. IDO expression has also reported in the epithelium of cervical glands and that of fallopian tubes (23).

Although there is considerable evidence on the indisputable role of IDO for the induction of maternal tolerance during pregnancy, little is known about localization of IDO in pregnant endometrium during this period. Therefore, we

investigated the expression of IDO in feto-placental unit throughout mouse gestation.

Materials and Methods

Animals: Inbred female Balb/c, 8-12-week mice (Pasteur Institute, Iran) were kept under optimal conditions of hygiene, temperature, humidity with 12-h light/dark intervals and were allowed food and water *ad libitum*. The study was approved by the ethics committee of Avicenna Research Institute.

Determination of gestational age: Female Balb/c mice were caged with syngeneic male mice and checked daily for the presence of vaginal plaque. Plaque positive female mice were selected and examined for the presence of sperm in vaginal smears. Only when both criteria of vaginal plaque and sperm presence were met, mice were considered to be at day 0.5 of gestation. A total of three pregnant mice were examined at each stage.

Preparation of polyclonal anti-IDO antibodies: Polyclonal IDO-specific antibodies were produced in rabbits as previously described by our group at Avicenna Research Institute (25). In brief, two synthetic peptides-encoding amino acid sequences from murine IDO were conjugated to thyroglobulin (Sigma, Sweden) and used for the production of polyclonal antibodies. Upon antibody titer rise, judged by ELISA, antibodies were purified by immunoaffinity chromatography columns. Reactivity of each antibody was determined by western blotting and immunohistochemistry tested on murine epididymis tissue as the positive control. Both antibodies had considerable reactivity in the aforementioned experiments (formation of a single band weighing 45KD in western blot and perinuclear staining of apical cells in caput epididymis), however, one of the antibodies (IDO-17) had stronger immuno-reactivity upon immunohistochemistry and hence in all subsequent immunohistochemical experiments this one was used.

Tissue preparation: On gestational days 2, 12 and 18, analogous to the early, middle and late murine gestational periods, the whole uterus was removed and opened along the anti-mesometrial line. The placenta with its underlying decidual tissues and the right oviduct were removed at each stage. Tissues were embedded in frozen glue (Junk, Denmark) and cut into 5 µm sections. Slides were

let to be air-dried for 4-6 hours and to be frozen at -20°C for later use.

Immunohistochemistry: Slides were fixed in cold Neutral Buffered Formalin (NBF) for 5 minutes and processed immediately for immunostaining. Slides were washed three times, three minutes each, by Tris-buffered saline containing 1% bovine serum albumin and were blocked in 5% normal sheep serum. After tilting, slides were incubated with anti-IDO antibody at a final concentration of $1\text{ }\mu\text{g/ml}$ for 90 min and washed three times as stated previously. Thereupon, endogenous peroxidase was quenched by treatment with 0.3% hydrogen peroxide (H_2O_2) for 10 minutes. After washing, $5\text{ }\mu\text{g/ml}$ of biotin-conjugated sheep anti-rabbit Ig (Avicenna Research Institute, Iran) was added and slides were incubated for a further 45 minutes. After another washing, the slides were treated with

1:250 dilution of HRP-conjugated streptavidin (Biosource, USA) for 30 minutes. At the final step, color was developed by the addition of 3, 3'-Diaminobenzidine (DAB) (Roche, Germany) for 10 minutes. Slides were then counterstained by Harris hematoxylin, and mounted with Entellan (Merck, Germany).

Results

This study was conducted in order to investigate immunolocalization of IDO positive cells at the fetomaternal interface of pregnant mice throughout the gestational period. To this end, polyclonal antibodies were produced and expression of IDO at the fetoplacental unit was tested by one of these antibodies named IDO-17.

In this study, IDO was expressed both at the maternal (decidua) and fetal sides of placenta in all stages of murine pregnancy. Glandular and




Figure 1. Immunohistochemical detection of IDO-positive cells in the endometrium of pregnant mice at different gestational periods. Uteri of syngeneic pregnant (Balb/c $\times$ Balb/c) mice were removed at early (a), mid (b) and late (c) gestational periods and immunostaining for IDO was carried out on the cryosections. In negative control slides (d), primary antibody was pre-adsorbed by an immunizing peptide with a 50-molar concentration. Black arrows show IDO positive cells (Magnification: 200 $\times$).




Figure 2. Localization of IDO in placenta of pregnant mice. At mid (a) and late (b) stages of syngeneic mouse pregnancy (Balb/c $\times$ Balb/c), placenta was immunostained by IDO-specific antibody. Fig.c: illustrates a representative negative control slide. Black arrows show IDO positive cells (Magnification: 200 $\times$).




Figure 3. IDO immunostaining of fallopian tubes at different stages of murine pregnancy. IDO-positive cells were immunolocalized in fallopian tubes of syngeneic pregnant (Balb/c $\times$ Balb/c) mice at early (a), mid (b) and late (c) gestational periods. Fig. d: negative control slide. Black arrows show IDO positive cells (Magnification: 200 $\times$).

luminal epithelial cells were the prominent cell type in decidua basalis that expressed IDO during the gestational period (Figure 1). In addition, there were scattered populations of IDO positive cells in the endometrial stroma. IDO positive cells were also present in decidua capsularis. Beneath this layer, cells of chorionic membrane were positive for IDO as well (data not shown). Expression of IDO in the aforesaid cell population was continued until the end of pregnancy.

The study demonstrated strong anti-IDO antibody reactivity at the fetal side of placenta in both middle and late gestational periods (Figure 2). On the fetal face of the placenta, cells of both junctional and labyrinthine zones (syncytial cells) showed strong IDO expression. Trophoblast giant cells at the junctional zone were among the cells with strong IDO expression (Figure 2, black arrows).

In all murine gestational stages, epithelial cells of the fallopian tubes were highly positive for IDO (Figure 3). Interestingly, the staining pattern of all cells was essentially perinuclear. When primary antibody was pre-adsorbed with immunizing peptide, no immunoreactivity was observed in negative reagent control slides confirming specificity of anti-IDO antibodies (Figures 1d, 2c and 3d).

Discussion

Based on the results presented in this paper, IDO is expressed consistently at the maternal (decidua) and fetal side of placenta throughout murine gestational period. There are conflicting reports on the kinetic of IDO expression during pregnancy. Suzuki *et al.* showed that IDO protein and its mRNA were not expressed during early murine gestation, but they appeared 2-3 days afterwards, lasting for about three days and declining rapidly thereafter (26). According to von Rango's study (27), IDO expression starts at the mid-luteal phase in the menstrual cycle and remains high until the second trimester of pregnancy. However, glandular expression of IDO decreases during the second trimester, whereas its expression in villous trophoblasts starts in the meantime. On the other hand, in an elegantly-designed study by Kudo *et al.*, IDO was detectable immunohistochemically from day 6 of human blastocysts and thereafter throughout pregnancy in syncytiotrophoblasts,

extravillous cytotrophoblasts and macrophages in the villous stroma and in the fetal membranes (28).

Recently, IDO localization in the reproductive tissues of rhesus monkeys was studied immunohistochemically by Drenzek *et al.* (29). Likewise, IDO was expressed in all gestational periods of the monkeys. Although findings on kinetic expression of IDO at the feto-placental unit are largely inconsistent, but considering the protective role of this molecule, its steady expression is conceivable. Notably, in a very recent report by our group (25), we showed that expression of IDO is started very soon before the conception takes place in the endometrium of cycling mice which is in line with the findings of Drenzek *et al.* (29) and von Rango (27). Outstandingly, IDO expression was largely limited to epithelial cells of endometrium of non-pregnant mice (25), indicating contribution of these cell types in the regulation of local innate immune system as confirmed in the present study. The same finding was reported by Drenzek *et al.* showing localization of IDO in the epithelial cell of non-pregnant and pregnant endometrium. At the placental level, we showed that placental giant cells and spongio-trophoblasts express IDO steadily in all gestational periods, which is supported by Drenzek *et al.* (29).

IDO expression contributes to the suppression of potentially harmful maternal immune responses. IDO on the cells of syncytiotrophoblasts helps the survival of semi-allograft transplant of fetus by suppressive effects on T-cell proliferative responses (20, 21, 23, 24, 26).

Ligam P. *et al.* also proposed a physiological activity for this enzyme at the feto-maternal interface which may contribute to the regulation of blood flow or placental metabolism [30]. Indeed, induction of IDO by IFN- γ blocks growth of intracellular parasites (*Toxoplasma gondii*, *Chlamydia psittaci*, etc) by tryptophan depletion (31, 32). In addition, an extracellular antibacterial effect has been reported for IDO as inhibiting the growth of *Enterococci* by IFN- γ -activated human uroepithelial cells (33). IDO in epithelial cells of fallopian tubes, as reported in this study, may serve the same role in preventing ascending urinary tract infections during pregnancy.

Conclusion

Collectively, this study showed IDO expression at the protein level in endometrium, fallopian tubes and placenta of pregnant mice during the entire gestational period, reflecting its potential protective role in maintaining pregnancy. Quantitative analysis of IDO expression and functional study of its activity during different stages of pregnancy will increase the understanding of IDO-dependent immunoregulation at fetomaternal interface.

Acknowledgement

The authors are grateful to Razi Medical Scientific Festival for its financial support by Grant Number 3356/T/MM.

References

- Shimizu T, Nomiya S, Hirata F, Hayaishi O. Indoleamine 2,3-dioxygenase. Purification and some properties. *J Biol Chem*. 1978;253(13):4700-6.
- Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. *J Biol Chem*. 1986; 261(8):3648-53.
- Werner ER, Bitterlich G, Fuchs D, Hausen A, Reibnegger G, Szabo G, et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. *Life Sci*. 1987;41(3):273-80.
- Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase and tryptophan catabolism. *FASEB J*. 1991;5(11): 2516-22.
- Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. *J Biol Chem*. 1988;263(4):2041-8.
- Aune TM, Pogue SL. Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide. *J Clin Invest*. 1989;84(3):863-75.
- Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. *Proc Natl Acad Sci U S A*. 1988;85(4):1242-6.
- Pfefferkorn ER. Interferon gamma blocks the growth of *Toxoplasma gondii* in human fibroblasts by inducing the host cells to degrade tryptophan. *Proc Natl Acad Sci U S A*. 1984;81(3):908-12.
- Gupta SL, Carlin JM, Pyati P, Dai W, Pfefferkorn ER, Murphy MJ Jr. Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts. *Infect Immun*. 1994;62(6):2277-84.
- Naginei CN, Pardhasaradhi K, Martins MC, Detrick B, Hooks JJ. Mechanisms of interferon-induced inhibition of *Toxoplasma gondii* replication in human retinal pigment epithelial cells. *Infect Immun*. 1996;64(10):4188-96.
- Yoshida R, Nukiwa T, Watanabe Y, Fujiwara M, Hirata F, Hayaishi O. Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. *Arch Biochem Biophys*. 1980;203(1):343-51.
- Yoshida R, Urade Y, Nakata K, Watanabe Y, Hayaishi O. Specific induction of indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide in the mouse lung. *Arch Biochem Biophys*. 1981;212(2): 629-37.
- Moffett JR, Espey MG, Namboodiri MA. Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. *Cell Tissue Res*. 1994;278(3):461-9.
- Malina HZ, Martin XD. Indoleamine 2,3-dioxygenase: antioxidant enzyme in the human eye. *Graefes Arch Clin Exp Ophthalmol*. 1996; 234(7):457-62.
- Yamazaki F, Kuroiwa T, Takikawa O, Kido R. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. *Biochem J*. 1985;230(3):635-8.
- Kamimura S, Eguchi K, Yonezawa M, Sekiba K. Localization and developmental change of indoleamine 2,3-dioxygenase activity in the human placenta. *Acta Med Okayama*. 1991;45(3):135-9.
- Frumento G, Rotondo R, Tonetti M, Ferrara GB. T cell proliferation is blocked by indoleamine 2,3-dioxygenase. *Transplant Proc*. 2001;33(1-2): 428-30.
- Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. *J Exp Med*. 1999;189(9):1363-72.
- Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase produc-

- tion by human dendritic cells results in the inhibition of T cell proliferation. *J Immunol.* 2000; 164(7):3596-9.
20. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. *Science.* 1998;281(5380):1191-3.
 21. Kudo Y, Boyd CA. Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. *Biochim Biophys Acta.* 2000;1500(1): 119-24.
 22. Mellor AL, Munn DH. Extinguishing maternal immune responses during pregnancy: implications for immunosuppression. *Semin Immunol.* 2001; 13(4):213-8.
 23. Sedlmayr P, Blaschitz A, Wintersteiger R, Semlitsch M, Hammer A, MacKenzie CR, et al. Localization of indoleamine 2,3-dioxygenase in human female reproductive organs and the placenta. *Mol Hum Reprod.* 2002;8(4):385-91.
 24. Kudo Y, Boyd CA, Sargent IL, Redman CW. Modulation of indoleamine 2,3-dioxygenase by interferon-gamma in human placental chorionic villi. *Mol Hum Reprod.* 2000;6(4):369-74.
 25. Jeddi-Tehrani M, Abbasi N, Dokouhaki P, Ghasemi J, Rezaei S, Ostadkarampour M, et al. Indoleamine 2,3-dioxygenase is expressed in endometrium of cycling mice throughout the estrous cycle. *J Reprod Immunol.* 2009;80(1-2):41-8.
 26. Suzuki S, Tone S, Takikawa O, Kubo T, Kohno I, Minatogawa Y. Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti. *Biochem J.* 2001;355(Pt 2):425-9.
 27. von Rango U, Krusche CA, Beier HM, Classen-Linke I. Indoleamine-dioxygenase is expressed in human decidua at the time maternal tolerance is established. *J Reprod Immunol.* 2007;74(1-2):34-45.
 28. Kudo Y, Boyd CA, Spyropoulou I, Redman CW, Takikawa O, Katsuki T, et al. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. *J Reprod Immunol.* 2004;61(2):87-98.
 29. Drenzek JG, Breburda EE, Burleigh DW, Bondarenko GI, Grendell RL, Golos TG. Expression of indoleamine 2,3-dioxygenase in the rhesus monkey and common marmoset. *J Reprod Immunol.* 2008;78(2):125-33.
 30. Ligam P, Manuelpillai U, Wallace EM, Walker D. Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy. *Placenta.* 2005;26(6):498-504.
 31. Byrne GI, Lehmann LK, Landry GJ. Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular *Chlamydia psittaci* replication in T24 cells. *Infect Immun.* 1986;53(2):347-51.
 32. Thomas SM, Garrity LF, Brandt CR, Schobert CS, Feng GS, Taylor MW, et al. IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular *Chlamydia* spp. or *Toxoplasma* growth. *J Immunol.* 1993;150(12):5529-34.
 33. MacKenzie CR, Hucke C, Muller D, Seidel K, Takikawa O, Daubener W. Growth inhibition of multiresistant enterococci by interferon-gamma-activated human uro-epithelial cells. *J Med Microbiol.* 1999;48(10):935-41.